News Search & Analytics
US Edition
Minimum 3 characters required!!
Report Based On Past 7 Days Data
9
Total Articles
6
Total Publisher Covering articles
3
Highest On 2017-03-21
0
Articles Got Popular On Social Media
gilead sciences found in Articles in last 7 Days

Top Articles

Oct 20 Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and...
Oct 20 Gilead Sciences Inc * Gilead announces SVR12 rates from four phase 3 studies of a once-daily, fixed-dose combination of Sofosbuvir, Velpatasvir and Voxilaprevir in treatment...
Sept 27 Gilead Sciences * Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration * Partnership with World Health Organization to ...
Oct 20 (Reuters) - Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertensi...
Nov 16 Gilead Sciences Inc : * Gilead Sciences Inc - non-inferiority was not achieved for key secondary endpoint of response rate in total symptom score (TSS) * Gilead announces to...
BRIEF-Gilead presents new phase 2 data on Bictegravir
-Reuters - Mon Feb 13 14:05:30 EST 2017
Feb 13 Gilead Sciences Inc : * Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV * Bictegravir in com...
Gilead Sciences, Inc. () has announced that it will be acquiring Nimbus Therapeutics’ Nimbus Apollo, Inc. subsidiary for up to $1.2 billion. Gilead Sciences will be paying $40...
July 22 Gilead Sciences Inc * European CHMP adopts positive opinion on Gilead's type II variation application for Truvada for reducing the risk of --- acquired HIV. * CHMP's ...
Obama on Turkish Coup, Fethullah Gülen, Erdogan Crackdown
-Investing - Mon Jul 25 17:10:22 EDT 2016
Shares in Gilead Sciences plunge 3% amid disappointing Harvoni sales Investing.com -- Shares in Gilead Sciences Inc (NASDAQ:GILD) fell sharply in after-hours trading after sales in...
June 23 Gilead Sciences Inc * European Commission grants marketing authorization for Gilead's single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for...
Aug 10 Genmab A/S : * Genmab enters commercial license agreement with Gilead for DuoBody(R) Technology * Genmab is entitled to potential development, regulatory and sales milestone...
Why Gilead Sciences Shares Fell 7% in October | Fox Business
-Fox Business - Tue Nov 08 13:53:26 EST 2016
Image source: Getty Images. Worries that hepatitis C sales will remain a headwind to top- and bottom-line growth caused Gilead Sciences (NASDAQ: GILD) shares to decline 7% in Octob...
Gilead Shares Fall After Company Misses On Revenue | Fox Business
-Fox Business - Thu Apr 28 14:05:25 EDT 2016
Gilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biotech company reported lower-than-expected first-quarter sales. Gilead said it earned an adjusted $4.3 ...
Gilead to pay $400 million for drug candidate - The Denver Post
-The Denver Post - Tue Apr 05 02:07:51 EDT 2016
Gilead Sciences on Monday said it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes life-threaten...
Image source: Gilead Sciences, Inc. While following blindly in the footsteps of billionaires is risky, it's always interesting to see what stocks legendary investing gurus are sell...
SOURCE: FLICKR USER BILL BROOKS. A jury in Northern California has weighed in and decided that Gilead Sciences' mega-blockbuster drugs Sovaldi and Harvoni violate two patents co-ow...
EU regulators recommend approving Gilead's new hepatitis C drug
-Reuters - Fri May 27 08:14:34 EDT 2016
Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines...
U.S. FDA approves Gilead's hep C drug Epclusa
-Reuters - Tue Jun 28 08:16:38 EDT 2016
June 28 The U.S. Food and Drug Administration approved Gilead Sciences Inc's drug for treating chronic hepatitis C virus infection. The drug, Epclusa, is approved for use in combin...
BRIEF-Gilead Sciences prices $5 bln of senior unsecured notes
-Reuters - Thu Sep 15 20:14:16 EDT 2016
Sept 15 Gilead Sciences Inc : * Gilead prices $5 billion of senior unsecured notes * Priced $1.25 billion of 2.950% senior notes maturing in 2027 * Priced $750 million of 2.500% se...
After Rough Patch,Gilead Shouldn't Succumb to Deal Pressure
-The Wall Street Journal - Sun Nov 20 11:00:57 EST 2016
Gilead Sciences shareholders have faced unrelenting disappointment lately. The rough ride isn’t a reason to abruptly change its deal strategy, though. The latest blow: Gilead annou...
Gilead's Boom Fades and --- Will Linger
-The Wall Street Journal - Wed Feb 08 07:14:15 EST 2017
Gilead Sciences, perhaps the company most responsible for powering the last biotech bull market, has a revenue problem on its hands. Its struggles highlight how quickly the moment ...
Gilead Goes to the Head of the Line
-The Wall Street Journal - Tue Feb 21 10:11:23 EST 2017
A lack of deal activity at Gilead Sciences Inc. has lately frustrated shareholders. But company executives know a bargain when they see one. The biotech giant purchased a priority ...
Why You're Right to Invest in Gilead Sciences Stock | Fox Business
-Fox Business - Mon Jan 30 10:04:15 EST 2017
With the Dow Jones Industrial Average blasting through the 20,000 mark, many stocks are currently trading at or near their all-time highs. Unfortunately, biotechnology investors ha...
3 Reasons Gilead Sciences Is a Buy | Fox Business
-Fox Business - Fri Jun 17 14:05:24 EDT 2016
Drugmaking giant Gilead Sciences has fallen out of favor with investors because sales of its hepatitis C drugs are flat-lining, but shunning Gilead Sciences may not be best long-te...
Image source: Gilead Sciences. The Americans for Tax Fairness has sent a request to the Internal Revenue Service to launch an investigation into whetherGilead Sciences (NASDAQ: GIL...
The Pros and Cons of Buying Gilead Sciences Stock | Fox Business
-Fox Business - Thu Sep 22 08:04:46 EDT 2016
Image source: Stockmonkeys.com via Flickr. Gilead Sciences (NASDAQ: GILD) is a biotech Goliath generating $30 billion in annualized sales and $14 billion in annualized net income. ...
Gilead Sciences Inc. makes the two leading drugs that can quickly cure hepatitis C infections. But most patients can't afford the expensive drugs, and states restrict their use amo...
Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled...
(Reuters) - Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district jud...
Image source: Ionis Pharmaceuticals, Inc. A spat between Merck & Co. and Gilead Sciences that could have a big impact on Ionis Pharmaceuticals, Inc. has taken a turn for the wo...
Advertisement